These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28716995)

  • 1. Impact of GP reminders on follow-up of abnormal cervical cytology: a before-after study in Danish general practice.
    Kristiansen BK; Andersen B; Bro F; Svanholm H; Vedsted P
    Br J Gen Pract; 2017 Aug; 67(661):e580-e587. PubMed ID: 28716995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial.
    Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B
    BMC Cancer; 2018 Mar; 18(1):273. PubMed ID: 29523108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States.
    Hosier H; Sheth SS; Oliveira CR; Perley LE; Vash-Margita A
    Am J Obstet Gynecol; 2021 Dec; 225(6):649.e1-649.e9. PubMed ID: 34256029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Patient Reminders on Papanicolaou Test Completion for High-Risk Patients Identified by a Clinical Decision Support System.
    MacLaughlin KL; Kessler ME; Komandur Elayavilli R; Hickey BC; Scheitel MR; Wagholikar KB; Liu H; Kremers WK; Chaudhry R
    J Womens Health (Larchmt); 2018 May; 27(5):569-574. PubMed ID: 29297754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program.
    Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B
    BMC Cancer; 2016 Nov; 16(1):835. PubMed ID: 27809810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervical testing beyond the screening target age - A register-based cohort study from Finland.
    Keltto N; Leivonen A; Pankakoski M; Sarkeala T; Heinävaara S; Anttila A
    Gynecol Oncol; 2021 Aug; 162(2):315-321. PubMed ID: 34074539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How many cervical cancer cases can potentially be prevented using a more sensitive screening test at young age?
    de Kok IM; van Rosmalen J; Rozemeijer K; Penning C; van Ballegooijen M
    Int J Cancer; 2014 Jan; 134(2):460-6. PubMed ID: 23824905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
    Fontham ETH; Wolf AMD; Church TR; Etzioni R; Flowers CR; Herzig A; Guerra CE; Oeffinger KC; Shih YT; Walter LC; Kim JJ; Andrews KS; DeSantis CE; Fedewa SA; Manassaram-Baptiste D; Saslow D; Wender RC; Smith RA
    CA Cancer J Clin; 2020 Sep; 70(5):321-346. PubMed ID: 32729638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
    Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
    Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community-randomised controlled trial embedded in the Anishinaabek Cervical Cancer Screening Study: human papillomavirus self-sampling versus Papanicolaou cytology.
    Zehbe I; Jackson R; Wood B; Weaver B; Escott N; Severini A; Krajden M; Bishop L; Morrisseau K; Ogilvie G; Burchell AN; Little J
    BMJ Open; 2016 Oct; 6(10):e011754. PubMed ID: 27855089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
    Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
    Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
    Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
    Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of HPV testing on cervical cancer screening].
    Li G
    Zhonghua Fu Chan Ke Za Zhi; 2015 Apr; 50(4):241-5. PubMed ID: 26080933
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.